OncoMatch/Clinical Trials/NCT06639724

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

Is NCT06639724 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) for pancreatic ductal adenocarcinoma (pdac).

Phase 1RecruitingUniversity of California, San DiegoNCT06639724Data as of May 2026

Treatment: Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) — This is a Phase 1b trial evaluating the combination of Fostamatinib, a Syk kinase inhibitor currently FDA-approved for chronic idiopathic thrombocytopenia purpura (ITP), with the standard of care chemotherapy agents gemcitabine and nab-paclitaxel, for the perioperative treatment of resectable non metastatic pancreatic ductal adenocarcinoma (PDAC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any treatment for PDAC

Any prior treatment for PDAC

Cannot have received: investigational agent

Exception: within 28 days prior to the first dose of study drug

Received an investigational agent within 28 days prior to the first dose of study drug

Lab requirements

Blood counts

Absolute Neutrophil Count ≥ 1.5 x 10^9/L; Platelet count ≥ 100 x 10^9/L; Hemoglobin ≥ 9.0 g/dL

Kidney function

Serum creatinine ≤ 2 x institutional ULN

Liver function

AST/SGOT and ALT/SPGT ≤ 2.5 X institutional ULN; Total Bilirubin ≤ 1.5 x institutional ULN or ≤3 × institutional ULN in Gilbert's Ds

Patient has adequate organ function as defined below: Absolute Neutrophil Count ≥ 1.5 x 10^9/L; Platelet count ≥ 100 x 10^9/L; Hemoglobin ≥ 9.0 g/dL; AST/SGOT and ALT/SPGT ≤ 2.5 X institutional ULN; Total Bilirubin ≤ 1.5 x institutional ULN or ≤3 × institutional ULN in Gilbert's Ds; Serum creatinine ≤ 2 x institutional ULN

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

University of California, San Diego Moores Cancer Center · La Jolla, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify